Kazia Therapeutics Limited

ASX Code



Pharmaceuticals- Biotechnology & Life Sciences

Investor Centre





Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Kazia'spipeline includes two clinical-stage drug development candidates, and they are working to develop therapies across a range of oncology indications. Kazia's lead program is paxalisib (formerly GDC-0084), a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults. Licensed from Genentech in late 2016, paxalisib entered a phase II clinical trial in 2018. Interim data was reported in April 2020, and further data is expected in 2H 2020. Paxal


Kazia: AGILE Hurdle Missed but Significant Value Remains
Kazia Therapeutics (ASX: KZA) – Webinar presentation
Key Points To Remember When Investing in Biotech Companies
Due Diligence Webinar - Kazia Therapeutics
A high quality pipeline of cancer drugs
Alzheimer’s Decision Sends Positive Message to Aussie Biotechs
Kazia Licenses New Oncology Drug Candidate
Kazia Licenses Ovarian Cancer Drug to Swedish Pharmaceutical Company
Kazia Therapeutics (ASX:KZA) - Hidden Gems Webinar Presentation
Why Kazia Therapeutics is Australia's biotech shining star
Kazia's New Collaboration Gives Their Cancer Drug New Potential For Treatment Of Lymphoma
With A 'Ticket To Ride', Kazia Wows Investors With Its Rare-Cancer Story
Kazia Therapeutics - ShareCafe Hidden Gems Webinar Presentation


A Laser-Like Focus on Adding Value -5 Data Readouts in 9-Months
SNO Presentations: Late-Interim Results from Phase II GBM & Phase I DIPG Studies Released
Cantrixil Iicensed To Oasmia Pharmaceuticals & Kazia Shareholders Learn a Positive Lesson About Kazia
Do Two A+ Deals Foreshadow THE DEAL?
Another Deal – Kazia Inlicences New Anti-Cancer Med From Highly Impressive Partner
Biopharmas Hit, but Buying Opportunities Created Antisense (ANP) & Kazia (KZA), Two Companies To Build Your Biopharma Portfolio Around
Paxalisib Misses AGILE Hurdle, but Very Significant Value Remains